Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy

Abstract

Background The outlook for adolescents with Duchenne muscular dystrophy (DMD) has improved greatly as a result of corticosteroid use, but treatment will compromise growth and delay puberty. Whether exogenous testosterone can promote growth, development, and skeletal health is unclear.

Methods We collected data retrospectively on growth and pubertal response in 14 adolescents with DMD who were treated with testosterone between 2008 and 2014.

Results A total of 14 boys were treated at a median age of 14.5 years. Eight have finished treatment after a mean age of 3.1 years and the feedback from families was generally positive. The mean testicular volume pretreatment was 2.4 and 3.9 mL posttreatment. The mean baseline testosterone concentrations were < 1.0 and 5.4 nmol/L postintervention. Median height velocity increased from 0.45 cm/y before treatment to 3.6 cm/y after the treatment. The mean height gain was 14.2 cm.

Conclusions A broad range of testosterone preparations was used. Testosterone was generally well-liked, but side effects were experienced by some patients and the pubertal growth increment appears to be compromised. Few subjects had adult endogenous testosterone levels posttreatment. Controlled studies are required to determine the most appropriate treatment regimen and the precise impact of testosterone on key outcomes, such as muscle function and bone integrity. Clinicians will then be better placed to advise families about likely benefits and risks.

Keywords

Duchenne muscular dystrophy - growth - puberty - hypogonadism - corticosteroids - testosterone

• References

• 1 Emery AE. Population frequencies of inherited neuromuscular diseases—a world survey. Neuromuscul Disord 1991; 1 (1) 19-29
• 2 Bushby K, Finkel R, Birnkrant DJ , et al; DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010; 9 (1) 77-93
• 3 Moxley III RT, Pandya S, Ciafaloni E, Fox DJ, Campbell K. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 2010; 25 (9) 1116-1129
• 4 Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy. Biochim Biophys Acta 2007; 1772 (2) 229-237
• 5 Markham LW, Kinnett K, Wong BL, Woodrow Benson D, Cripe LH. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromuscul Disord 2008; 18 (5) 365-370
• 6 Daftary AS, Crisanti M, Kalra M, Wong B, Amin R. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics 2007; 119 (2) e320-e324
• 7 Lebel DE, Corston JA, McAdam LC, Biggar WD, Alman BA. Glucocorticoid treatment for the prevention of scoliosis in children with Duchenne muscular dystrophy: long-term follow-up. J Bone Joint Surg Am 2013; 95 (12) 1057-1061
• 8 Mason A, Wong SC, McGrogan P, Ahmed SF. Effect of testosterone therapy for delayed growth and puberty in boys with inflammatory bowel disease. Horm Res Paediatr 2011; 75 (1) 8-13
• 9 Landon C, Rosenfeld RG. Short stature and pubertal delay in male adolescents with cystic fibrosis. Androgen treatment. Am J Dis Child 1984; 138 (4) 388-391
• 10 Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17 (4) 407-429
• 11 Cole TJ. Growth monitoring with the British 1990 growth reference. Arch Dis Child 1997; 76 (1) 47-49
• 12 Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 2006; 16 (4) 249-255
• 13 Merlini L, Gennari M, Malaspina E , et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve 2012; 45 (6) 796-802
• 14 Rapaport D, Colletto GM, Vainzof M, Duaik MC, Zatz M. Short stature in Duchenne muscular dystrophy. Growth Regul 1991; 1 (1) 11-15
• 15 Rutter MM, Collins J, Rose SR , et al. Growth hormone treatment in boys with Duchenne muscular dystrophy and glucocorticoid-induced growth failure. Neuromuscul Disord 2012; 22 (12) 1046-1056
• 16 Bianchi ML, Biggar D, Bushby K, Rogol AD, Rutter MM, Tseng B. Endocrine aspects of Duchenne muscular dystrophy. Neuromuscul Disord 2011; 21 (4) 298-303
• 17 Nereo NE, Fee RJ, Hinton VJ. Parental stress in mothers of boys with duchenne muscular dystrophy. J Pediatr Psychol 2003; 28 (7) 473-484
• 18 Zacharin MR, Warne GL. Treatment of hypogonadal adolescent boys with long acting subcutaneous testosterone pellets. Arch Dis Child 1997; 76 (6) 495-499
• 19 Katznelson L, Finkelstein JS, Schoenfeld DA, Rosenthal DI, Anderson EJ, Klibanski A. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81 (12) 4358-4365
• 20 Brodsky IG, Balagopal P, Nair KS. Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 1996; 81 (10) 3469-3475
• 21 Fenichel GM, Griggs RC, Kissel J , et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 2001; 56 (8) 1075-1079
• 22 Stanhope R, Preece MA. Management of constitutional delay of growth and puberty. Arch Dis Child 1988; 63 (9) 1104-1110
• 23 Henricson EK, Abresch RT, Cnaan A , et al; CINRG Investigators. The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve 2013; 48 (1) 55-67
• 24 Tanner JM, Whitehouse RH. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 1976; 51 (3) 170-179